Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 7.5% – Should You Sell?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)’s stock price was down 7.5% on Monday . The stock traded as low as $38.18 and last traded at $39.63. Approximately 290,583 shares changed hands during mid-day trading, an increase of 480% from the average daily volume of 50,104 shares. The stock had previously closed at $42.84.

Neoleukin Therapeutics Stock Down 7.5%

The stock has a market cap of $372.44 million, a P/E ratio of -12.74 and a beta of 1.11. The stock has a fifty day simple moving average of $30.43 and a 200-day simple moving average of $23.98.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.

The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.